Please save/export the filled in form as PDF before submitting it to Ugeskrift for Læger or Danish Medical Journal.

Date: 3. oktober 2022		
Your name: Andreas Røder		
Manuscript title: Prostatakræft		
Manuscript number (if known):		

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Tim	e frame: Since the initial plar	ning of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	⊠ None	

Click TAB in last row to add extra rows

#### Time frame: past 36 months

2	Grants or contracts from	☐ None	
	any entity (if not indicated	Pfizer A/S	Research grant. Translational research "DNA of
	in item #1 above).		Prostate Cancer"
		Novo Nordisk	Research grant. Kidney transplantation
		Foundation	
		Danish Cancer Society	Research grant. Late effects of Prostate Cancer
			treatment
		Alfred Benzon	Research Grant. Prostate artery embolization vs.
		Foundation	transurethral microwave therapy.

3	Royalties or licenses	None     Non
4	Consulting fees	⊠ None
-	oonsuming rees	None
5	Payment or honoraria for	□ None
	lectures, presentations,	Bayer A/S
	speakers bureaus,	Pfizer A/S
	manuscript writing or educational events	Astellas A/S
	educational events	Orion Pharma
		Recordati A/S
		Århus Universitet
		Janssen
		MSD
		Lægernes
		Uddannelsesforening  Sundhadastyralan
		Sundhedsstyrelsen
		Region Hovedstaden Astra-Zeneca
		AStra-Zerieca
6	Payment for expert	None     Non
	testimony	
7	Command for add and line	
7	Support for attending	□ None
	meetings and/or travel	Astellas Pharma
		Janssen
		Ipsen
8	Patents planned, issued or	⊠ None
	pending	
9	Participation on a Data	
		None     Non
	Safety Monitoring Board	MSD
		MSD Astra-Zeneca
	Safety Monitoring Board	MSD
10	Safety Monitoring Board or Advisory Board	MSD Astra-Zeneca Janssen
10	Safety Monitoring Board or Advisory Board  Leadership or fiduciary	MSD Astra-Zeneca
10	Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board,	MSD Astra-Zeneca Janssen
10	Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or	MSD Astra-Zeneca Janssen
10	Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board,	MSD Astra-Zeneca Janssen
	Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	MSD Astra-Zeneca Janssen
10	Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or	MSD Astra-Zeneca Janssen
	Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	MSD Astra-Zeneca  Janssen  None
	Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	MSD Astra-Zeneca  Janssen  None
11	Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options	MSD Astra-Zeneca  Janssen  None  None
	Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options  Receipt of equipment,	MSD Astra-Zeneca  Janssen  None
11	Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options  Receipt of equipment, materials, drugs, medical	MSD Astra-Zeneca  Janssen  None  None
11	Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options  Receipt of equipment, materials, drugs, medical writing, gifts or other	MSD Astra-Zeneca  Janssen  None  None
11	Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options  Receipt of equipment, materials, drugs, medical	MSD Astra-Zeneca  Janssen  None  None

Other financial or non-	
financial interests	

 $\boxtimes$  I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal

Date	<b>e</b> : 5. oktober 2022		
You	r name: Mads Hvid Pouls	sen	
Mai	nuscript title: Pros	statacancer	
-	nuscript number (if known)		
are re third comr	elated to the content of you parties whose interests ma	ur manuscript. "Related" ay be affected by the cont nd does not necessarily in	relationships/activities/interests listed below that means any relation with for-profit or not-for-profit tent of the manuscript. Disclosure represents a dicate a bias. If you are in doubt about whether to bu do so.
	following questions apply to uscript only.	o the author's relationship	os/activities/interests as they relate to the <u>current</u>
perta	ins to the epidemiology of	hypertension, you should	defined broadly. For example, if your manuscript declare all relationships with manufacturers of ot mentioned in the manuscript.
	m #1 below, report all support items, the time frame for	•	d in this manuscript without time limit. For all months.
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time	e frame: Since the initial plan		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	⊠ None	
	No time limit for this item.		
			Click TAB in last row to add extra rows
Time	e frame: past 36 months		
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None     Non	

4	Consulting fees	⊠ None
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None
6	Payment for expert testimony	None
7	Support for attending meetings and/or travel	None
8	Patents planned, issued or pending	⊠ None
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None None
11	Stock or stock options	None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None None
13	Other financial or non-financial interests	⊠ None

 $\boxtimes$  I certify that I have answered every question and have not altered the wording of any of the questions on this form.

#### IMPORTANT for Ugeskrift for Læger & Danish Medical Journal

Date	e: 4. oktober 2022		
You	<b>r name:</b> Henrik Jakobser	า	
Mai	nuscript title: Pro	ostatakræft	
Mai	<b>nuscript number</b> (if known	):	
are re third comr	elated to the content of yo parties whose interests ma	ur manuscript. "Related" ay be affected by the cont nd does not necessarily in	relationships/activities/interests listed below that means any relation with for-profit or not-for-profit ent of the manuscript. Disclosure represents a dicate a bias. If you are in doubt about whether to bu do so.
	ollowing questions apply to uscript only.	o the author's relationship	os/activities/interests as they relate to the <u>current</u>
perta antih In ite	ins to the epidemiology of ypertensive medication, ev	hypertension, you should yen if that medication is n port for the work reported	defined broadly. For example, if your manuscript declare all relationships with manufacturers of ot mentioned in the manuscript.  d in this manuscript without time limit. For all months.
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time	e frame: Since the initial plan	nning of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	⊠ None	
	No time limit for this		
	item.		
			Click TAB in last row to add extra rows
Time	e frame: past 36 months		
2	Country on anything star forms		
2	Grants or contracts from any entity (if not indicated	<b>⋈</b> None	
	in item #1 above).		
3	Royalties or licenses	□ None	
	,	Royalties som forfatter på Basisbog i Medicin & kirurgi 8. udgave	Meget små beløb

4	Consulting fees	<b>⊠</b> None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	□ None	
		Tilrettelæggelse og chairman ved "Prostata Cancer Forum", symposium 2019 og 2022	Honoreret af MSD, Astellas og Bayer i fællesskab, men alene tilrettelagt af urologer og onkologer i styregruppen
6	Payment for expert	<b>⊠</b> None	
	testimony	Zivone	
7	Support for attending meetings and/or travel	⊠ None	
8	Patents planned, issued or	⊠ None	
	pending		
9	Participation on a Data	<b>⊠</b> None	
	Safety Monitoring Board	Mone	
	or Advisory Board		
10	Leadership or fiduciary	<b>⊠</b> None	T
	role in other board, society, committee or		
	advocacy group, paid or		
	unpaid		
11	Stock or stock options	<b>⊠</b> None	
12	Receipt of equipment, materials, drugs, medical	<b>⊠</b> None	I
	writing, gifts or other		
	services		
13	Other financial or non-	<b>⊠</b> None	
	financial interests		

 $oxed{\boxtimes}$  I certify that I have answered every question and have not altered the wording of any of the questions on this form.

MPORTANT for Ugeskrift for Læger & Danish Medical Journal Please save/export the filled in form as PDF before submitting it to Ugeskrift for Læger or Danis Medical Journal.	h

Dat	<b>e</b> : 6. oktober 2021		
You	I <b>r name</b> : John Brandt Bro	odersen	
Mai	nuscript title: Statusa	artikel: Prostatakræft	
-	nuscript number (if known	):	
are re third comr	elated to the content of yo parties whose interests ma	ur manuscript. "Related" ay be affected by the cont nd does not necessarily in	relationships/activities/interests listed below that means any relation with for-profit or not-for-profit tent of the manuscript. Disclosure represents a dicate a bias. If you are in doubt about whether to bu do so.
	following questions apply to uscript only.	o the author's relationship	os/activities/interests as they relate to the <u>current</u>
perta	ains to the epidemiology of	hypertension, you should	defined broadly. For example, if your manuscript declare all relationships with manufacturers of ot mentioned in the manuscript.
	em #1 below, report all sup r items, the time frame for		d in this manuscript without time limit. For all months.
		Name all entities with	Specifications/Comments
		whom you have this relationship or indicate none (add rows as needed)	(e.g., if payments were made to you or to your institution)
Tim	e frame: Since the initial plan	relationship or indicate none (add rows as needed)	(e.g., if payments were made to you or to your
Tim 1	e frame: Since the initial plan All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	relationship or indicate none (add rows as needed)	(e.g., if payments were made to you or to your
-	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges,	relationship or indicate none (add rows as needed) nning of the work	(e.g., if payments were made to you or to your
-	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this	relationship or indicate none (add rows as needed) nning of the work	(e.g., if payments were made to you or to your
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this	relationship or indicate none (add rows as needed) nning of the work	(e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	relationship or indicate none (add rows as needed) nning of the work	(e.g., if payments were made to you or to your institution)
Tim 2	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from any entity (if not indicated in item #1 above).	relationship or indicate none (add rows as needed) nining of the work  None	(e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from any entity (if not indicated	relationship or indicate none (add rows as needed) nning of the work  None	(e.g., if payments were made to you or to your institution)

4	Consulting fees	⊠ None
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	⊠ None
6	Payment for expert testimony	None
7	Support for attending meetings and/or travel	None
8	Patents planned, issued or pending	⊠ None
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None None
11	Stock or stock options	None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None
13	Other financial or non-financial interests	⊠ None

 $\boxtimes$  I certify that I have answered every question and have not altered the wording of any of the questions on this form.

#### IMPORTANT for Ugeskrift for Læger & Danish Medical Journal

Dat	e: 3. oktober 2022		
You	<b>r name</b> : Jimmi Sønderga	ard	
Mai	nuscript title: Statusa	artikel Cancer prostata	
Mai	nuscript number (if known	):	
are re third comr	elated to the content of yo parties whose interests ma	ur manuscript. "Related" ay be affected by the con- nd does not necessarily in	relationships/activities/interests listed below that means any relation with for-profit or not-for-profit tent of the manuscript. Disclosure represents a dicate a bias. If you are in doubt about whether to bu do so.
	ollowing questions apply to uscript only.	o the author's relationship	os/activities/interests as they relate to the <u>current</u>
perta	ins to the epidemiology of	hypertension, you should	defined broadly. For example, if your manuscript declare all relationships with manufacturers of ot mentioned in the manuscript.
	m #1 below, report all suppritems, the time frame for		d in this manuscript without time limit. For all months.
		Name all entities with	Specifications/Comments
		whom you have this relationship or indicate none (add rows as needed)	(e.g., if payments were made to you or to your institution)
Time	e frame: Since the initial plan	relationship or indicate none (add rows as needed)	
Time	e frame: Since the initial plan All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	relationship or indicate none (add rows as needed)	
_	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges,	relationship or indicate none (add rows as needed) ning of the work	
_	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this	relationship or indicate none (add rows as needed) ning of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this	relationship or indicate none (add rows as needed) ning of the work	institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	relationship or indicate none (add rows as needed) ning of the work  None	institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	relationship or indicate none (add rows as needed) ning of the work	institution)
Time 2	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from any entity (if not indicated in item #1 above).	relationship or indicate none (add rows as needed) ining of the work  None  None  None  2022 Danish Comprehensive Cancer Center	Click TAB in last row to add extra rows  200000 kr. Project title - Dual-Energy CT til
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from any entity (if not indicated	relationship or indicate none (add rows as needed) ning of the work  None  None  None  2022 Danish Comprehensive Cancer	Click TAB in last row to add extra rows  200000 kr. Project title - Dual-Energy CT til

4	Consulting fees	None     Non	
5	Payment or honoraria for	None	
	lectures, presentations, speakers bureaus, manuscript writing or educational events		
	Dayma and fare assessed		
6	Payment for expert testimony		
	testimony		
7	Support for attending	None	
	meetings and/or travel		
8	Patents planned, issued or	None     Non	
	pending		
9	Participation on a Data	None     Non	
	Safety Monitoring Board or Advisory Board		
	of Advisory Board		
10	Leadership or fiduciary	None     Non	
	role in other board,		
	society, committee or advocacy group, paid or		
	unpaid		
	· · · · · · · · · · · · · · · · · · ·		
11	Stock or stock options	None	
12	Receipt of equipment,	None     Non	
	materials, drugs, medical		
	writing, gifts or other services		
	301 #1003		
13	Other financial or non-	None     Non	
	financial interests		

 $\boxtimes$  I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal

Please save/export <b>the filled in form as PDF before submitting</b> it to Ugeskrift for Læger or Danish Medical Journal.

Dat	e: 3. oktober 2022		
You	Ir name: Michael Borre		
		akræft	
	nuscript number (if known		
iviai	nuscript number (ii known	<i>)</i> .	
are re third comr list a	elated to the content of yo parties whose interests m mitment to transparency a relationship/activity/inter	ur manuscript. "Related" ay be affected by the control does not necessarily in est, it is preferable that yo	
	following questions apply t uscript only.	o the author's relationship	ps/activities/interests as they relate to the <u>current</u>
perta antih In ite	ains to the epidemiology of hypertensive medication, e	hypertension, you should yen if that medication is n port for the work reporte	defined broadly. For example, if your manuscript d declare all relationships with manufacturers of not mentioned in the manuscript.  d in this manuscript without time limit. For all months
Otrici	r items, the time frame for	disclosure is the pust so i	nontris.
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Tim	e frame: Since the initial plar	•	
1	All support for the present manuscript (e.g., funding,	None     Non	
	provision of study materials, medical writing, article processing charges, etc.)		
	materials, medical writing, article processing charges,		
	materials, medical writing, article processing charges, etc.)  No time limit for this		Click TAB in last row to add extra rows
Time	materials, medical writing, article processing charges, etc.)  No time limit for this		Click TAB in last row to add extra rows
Time 2	materials, medical writing, article processing charges, etc.)  No time limit for this item.  e frame: past 36 months  Grants or contracts from	None	Click TAB in last row to add extra rows
	materials, medical writing, article processing charges, etc.)  No time limit for this item.  e frame: past 36 months	None	Click TAB in last row to add extra rows
	materials, medical writing, article processing charges, etc.)  No time limit for this item.  e frame: past 36 months  Grants or contracts from any entity (if not indicated	None     None     None     None     None	Click TAB in last row to add extra rows

4	Consulting fees	None     Non	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	□ None Educational lectures	Janssen, Bayer, MSD, Astellas, Ferring
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None     Non	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary	□ None	
	role in other board, society, committee or advocacy group, paid or unpaid	Chairman Chairman	Danish Prostate Cancer Group (DAPROA)  Ass. Of the Danish Multidisciplinary Cancer Groups
11	Stock or stock options	None     Non	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	⊠ None	

 $\boxtimes$  I certify that I have answered every question and have not altered the wording of any of the questions on this form.

#### IMPORTANT for Ugeskrift for Læger & Danish Medical Journal